Key Focus

  • Moderna reports positive data on early-stage coronavirus vaccine trial, shares surge
    Mderna's closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, the biotech company announced Monday, sending the company's shares surging more than 17%.
    Each participant received a 25, 100 or 250 microgram dose, with 15 people in each dose group
  • Data on neutralizing antibodies for the other participants were not yet available, Moderna said.
    "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 [micrograms]," Moderna chief medical officer Dr. Tal Zaks said in a statement.
    "When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials," Zaks added.
    Moderna CEO on the promising preliminary results of early-stage Covid-19 study
    Scientists hope the antibodies provide some degree of protection against getting Covid-19, but they can't say that definitively yet since it hasn't been studied and some patients appear to have been reinfected after recovering from the virus.
    There are no formally approved treatments for Covid-19, which has killed at least 315,225 and sickened 4.7 million people worldwide since emerging from the Chinese city of Wuhan more than four months ago, according to Johns Hopkins University


To understand how to read this report, please click here

Knowledge Graph(Read more)

Complex Event Analysis(Read more)


High Level Topics

  • VACCINE
  • COVID-19
  • MODERNA
  • High Level Abstractions

  • VACCINE(4, 0 Order)
  • ( VACCINE )(4, 0 Order)  top
  • ( VACCINE, COVID-19 )(3, 1st Order)  top
  • ( VACCINE, COVID-19, ANTIBODIES )(2, 2nd Order)  top
  • ( VACCINE, COVID-19, MODERNA )(1, 2nd Order)  top
  • ( VACCINE, COVID-19, EARLY-STAGE )(2, 2nd Order)  top
  • ( VACCINE, COVID-19, MRNA-1273 )(1, 2nd Order)  top
  • ( VACCINE, COVID-19, CORONAVIRUS )(1, 2nd Order)  top
  • ( VACCINE, COVID-19, ZAKS )(1, 2nd Order)  top
  • ( VACCINE, COVID-19, WUHAN )(1, 2nd Order)  top
  • ( VACCINE, ANTIBODIES )(3, 1st Order)  top
  • ( VACCINE, ANTIBODIES, MODERNA )(1, 2nd Order)  top
  • ( VACCINE, ANTIBODIES, MRNA-1273 )(1, 2nd Order)  top
  • ( VACCINE, ANTIBODIES, MICROGRAM )(2, 2nd Order)  top
  • ( VACCINE, ANTIBODIES, EARLY-STAGE )(2, 2nd Order)  top
  • ( VACCINE, ANTIBODIES, CORONAVIRUS )(1, 2nd Order)  top
  • ( VACCINE, ANTIBODIES, ZAKS )(1, 2nd Order)  top
  • ( VACCINE, MODERNA )(2, 1st Order)  top
  • ( VACCINE, EARLY-STAGE )(2, 1st Order)  top
  • ( VACCINE, CORONAVIRUS )(2, 1st Order)  top
  • ( VACCINE, VACCINES )(2, 1st Order)  top
  • ( VACCINE, MRNA-1273 )(1, 1st Order)  top
  • ( VACCINE, MICROGRAM )(2, 1st Order)  top
  • COVID-19(4, 0 Order)
  • ( COVID-19 )(4, 0 Order)  top
  • ( COVID-19, ANTIBODIES )(3, 1st Order)  top
  • ( COVID-19, ANTIBODIES, MODERNA )(1, 2nd Order)  top
  • ( COVID-19, ANTIBODIES, MICROGRAM )(2, 2nd Order)  top
  • ( COVID-19, ANTIBODIES, EARLY-STAGE )(2, 2nd Order)  top
  • ( COVID-19, ANTIBODIES, MRNA-1273 )(1, 2nd Order)  top
  • ( COVID-19, ANTIBODIES, MICROGRAMS )(1, 2nd Order)  top
  • ( COVID-19, ANTIBODIES, CORONAVIRUS )(1, 2nd Order)  top
  • ( COVID-19, MODERNA )(1, 1st Order)  top
  • ( COVID-19, MICROGRAM )(2, 1st Order)  top
  • ( COVID-19, EARLY-STAGE )(2, 1st Order)  top
  • ( COVID-19, MICROGRAMS )(1, 1st Order)  top
  • ( COVID-19, CORONAVIRUS )(1, 1st Order)  top
  • ( COVID-19, ZAKS )(1, 1st Order)  top
  • MODERNA(2, 0 Order)
  • ( MODERNA )(2, 0 Order)  top
  • References